GlassScriptPhysician profile
Sara Welinsky
NPI 1801213053
$4,127.61
in general payments reported to CMS, 2019-2025
22 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $290 · 2021: $344 · 2022: $498 · 2023: $592 · 2024: $905 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,225 · Travel and Lodging: $772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,224.63 |
| Travel and Lodging | $771.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,141.95 | 2020-2025 | Apollo Esg Nxt System, Axios, Apollo Esg System |
| Abbvie INC. | $582.32 | 2020-2025 | Skyrizi, Rinvoq, Mavyret |
| Erbe USA INC | $268.06 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $255.40 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Conmed Corporation | $171.41 | 2020-2025 | Conmed Biliary |
| Janssen Biotech, INC. | $113.86 | 2022-2024 | Stelara, Simponi Aria, Simponi |
| Ardelyx, INC. | $107.50 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $86.40 | 2024 | Omvoh |
| Qol Medical, LLC | $54.32 | 2025 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $46.66 | 2022-2023 | Entyvio |
| Redhill Biopharma INC. | $46.45 | 2022-2023 | Talicia |
| Olympus America INC. | $40.87 | 2022-2025 | Endoclot Phs |
| Pfizer INC. | $32.16 | 2023 | |
| Vivus LLC | $30.00 | 2022 | |
| Gilead Sciences, INC. | $27.43 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $21.46 | 2024 | Sutab, Suflave |
| Aimmune Therapeutics, INC. | $21.26 | 2025 | Vowst |
| Capsovision, INC. | $18.45 | 2023 | Capsocam Plus |
| Intercept Pharmaceuticals, INC. | $17.00 | 2023 | Ocaliva |
| Ferring Pharmaceuticals INC. | $15.29 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $14.94 | 2022 | |
| Celgene Corporation | $14.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Welinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.